Navigation Links
A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
Date:1/14/2008

BOLDON, England, January 14 /PRNewswire/ -- IDS is pleased to announce that their new, unique immunoassay Rat/Mouse PINP- the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*, is now available.

The IDS Rat/Mouse P1NP is the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*. The use of this assay will aid the assessment of new osteoporosis drug candidates in pre-clinical studies and is therefore ideal for Pharmaceutical, Clinical and Academic Research Organizations alike.

The IDS Rat/Mouse PINP EIA is very flexible and measures PINP released from collagen synthesis in rats or mice (plasma or serum). The cross-reactivity with human-derived P1NP is not detectable.

The assay is very simple to perform and results are available in under 3 hours. The assay format and quality also allows one operator to perform over 160 tests per day ensuring high sample throughput and precise, sensitive results.

The combination of 8 well microtiter strips and up to 12 months shelf life also makes this kit ideal for academic researchers with low sample throughput providing quicker and more cost-effective results.

The IDS PINP EIA further expands the range what we believe to be the largest range of Bone & Cartilage Immunoassays available globally.

* Additional Information

The generation of type I collagen is a crucial step in bone formation where type I collagen is the major organic component of bone matrix. Propeptides are cleaved from both the N- and C-terminal ends of the procollagen molecule in equimolar concentrations during collagen synthesis. Thus, the quantification of N-terminal propeptide of type I procollagen (PINP) provides measurement of collagen synthesis and/or bone formation.

Contact:

Dean Hutchinson

Head of Marketing,

IDS LTD.

Telephone: +44(0)191-519-6104

Fax: +44(0)191-519-0760

E-Mail: deanh@idsltd.com


'/>"/>
SOURCE IDS Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest
2. Study Reaffirms Superiority of Trofile(TM) Assay
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
5. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
6. Assay Designs(TM) Announces Additions to the Leadership Team
7. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):